HJLI insider filings
Hancock Jaffe Laboratories, Inc. — 14 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2021-08-27. Screen HJLI transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for HJLI between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Hancock Jaffe Laboratories, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2021-08-27 | 4 | Jenusaitis Matthew — Director | Purchase (P): 1,300 @ $7.70 | EDGAR |
| 2021-06-21 | 4 | Gray Robert — Director | Purchase (P): 2,000 @ $6.25 | EDGAR |
| 2021-05-25 | 4 | Glickman Marc H. — SVP & Chief Medical Officer | Purchase (P): 1,600 @ $5.90 | EDGAR |
| 2021-05-19 | 4 | Duhay Francis — Director | Purchase (P): 9,492 @ $5.33 | EDGAR |
| 2021-05-19 | 4 | BERMAN ROBERT ANDREW — Chief Executive Officer, Director | Purchase (P): 3,000 @ $5.47 | EDGAR |
| 2021-02-23 | 4 | Glynn Craig — Chief Financial Officer | Grant/award (A): 4,000 (derivative) @ $0 · Grant/award (A): 324,000 (derivative) @ $0 | EDGAR |
| 2021-02-22 | 4 | Duhay Francis — Director | Grant/award (A): 5,673 (derivative) @ $0 | EDGAR |
| 2021-02-22 | 4 | Shrivastava Sanjay — Director | Grant/award (A): 5,673 (derivative) @ $0 | EDGAR |
| 2021-02-22 | 4 | Gray Robert — Director | Grant/award (A): 5,673 (derivative) @ $0 | EDGAR |
| 2021-02-22 | 4 | Glickman Marc H. — SVP & CMO | Grant/award (A): 406,000 (derivative) @ $0 | EDGAR |
| 2021-02-22 | 4 | Jenusaitis Matthew — Director | Grant/award (A): 5,673 (derivative) @ $0 | EDGAR |
| 2021-02-22 | 4 | BERMAN ROBERT ANDREW — Chief Executive Officer | Grant/award (A): 838,000 (derivative) @ $0 | EDGAR |
| 2020-10-21 | 4 | Jenusaitis Matthew — Director | Grant/award (A): 62,500 @ $0 · Grant/award (A): 78,125 (derivative) @ $0 · Grant/award (A): 60,000 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2020-10-01 | 4 | Biodyne Holding, S.A. | Sale (S): 100,000 @ $0.39 · Sale (S): 100,000 @ $0.42 · Sale (S): 150,000 @ $0.43 · Sale (S): 203,100 @ $0.48 · Sale (S): 61,640 @ $0.45 · Sale (S): 80,000 @ $0.46 · +21 more | EDGAR |
Recent 8-K events — Hancock Jaffe Laboratories, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-07-14 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-29 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-04 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-20 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-12 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-20 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-14 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-30 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-10 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-20 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=HJLI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs